Navigation Links
Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting

MONTREAL, Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral presentation at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, on December 9, 2008.

The presentation is entitled "Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML". The trial was an open label, multi-center study evaluating the safety and efficacy of AEG35156 in combination with chemotherapy in AML patients in first relapse after a short initial CR or with primary refractory disease. A total of 51 patients were enrolled in the study. The results demonstrate that AEG35156 is well tolerated at 350 mg/m2 in combination with idarubicin and cytarabine. The results also support the finding that AEG35156 combination therapy may induce high response rates in AML patients not responding to frontline induction therapy. Updated results on additional patients will be presented at the ASH Annual Meeting.

The study's principal investigator, Dr. Aaron D. Schimmer, M.D., Ph.D. of the Princess Margaret Hospital in Toronto will present the results of this study at the ASH session entitled "Acute Myeloid Leukemia - Therapy, Excluding Transplantation".

In addition, PD data from the same study will be presented by Dr. Carter Bing of the MD Anderson Cancer Center in a poster on December 7 under the title "Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML".

Details of each of these presentations are listed below.

2008 ASH Annual Meeting ASH - Oral Presentation

Title: Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156)

in Combination with Idarubicin and Cytarabine in Patients with

Relapsed/Refractory AML

Session Name: Acute Myeloid Leukemia - Therapy, Excluding Transplantation

Session Date: Tuesday, December 9th, 2008 Presentation Time: 7:45 AM

Session Location: Moscone Center, Room 3020-3022-3024 - West

2008 ASH Annual Meeting - Poster Presentation

Title: Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense

Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients

with Relapsed/Refractory AML

Abstract: #1943, Poster Board # II-37

Session Date: Sunday, December 7th, 2008

Session Time: 6:00 PM - 8:00 PM

Session Location: Moscone Center, Hall A

About AEG35156

AEG35156, a second generation antisense which targets XIAP, is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy. Aegera's published data with AEG35156, both in vitro and in vivo, strongly supports this hypothesis, and validates XIAP as a novel oncology drug target. The activity of AEG35156 is currently being explored, in combination, or as a monotherapy, in the following indications: acute myeloid leukemia, non-small cell lung cancer, hepatocarcinoma, and chronic lymphocytic leukemia and indolent B-cell lymphomas. The latter study is being conducted with the financial and scientific support of the Leukemia and Lymphoma Society through their innovative Therapy Acceleration Program.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. In addition to AEG35156, Aegera has three additional programs in clinical development for the treatment of cancer and neuropathic pain. Details of these programs can be found on Aegera's website at

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
2. Aegera Therapeutics welcomes two experienced executives to its board of directors
3. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
4. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
5. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
6. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
7. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Post Your Comments:
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between the ... has been formalized with the signing of a Memorandum of Understanding. , AMA ... Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/23/2015)... , October 23, 2015 ... announce a mobile plug and play integration of physiological ... tasks SensoMotoric Instruments (SMI) present a ... solutions for eye tracking and physiological data registration. It ... SMI Eye Tracking Glasses 2w and physiological signals ...
Breaking Biology News(10 mins):